{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:18:13Z","timestamp":1767651493995},"reference-count":55,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"unspecified","delay-in-days":1299,"URL":"https:\/\/www.cambridge.org\/core\/terms"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europsy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800068619_abs1\" sec-type=\"other\"><jats:title>Background<\/jats:title><jats:p>To present real-world evidence on the differences between long-acting injectable (LAI) and oral antipsychotic maintenance treatment (AMT) in terms of subjective well-being, attitudes towards drug and quality of life in a sample of remitted schizophrenic subjects.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800068619_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Twenty outpatients with remitted schizophrenia treated with either olanzapine or paliperidone and switching from the oral to the LAI formulation of their maintenance treatment were recruited before the switch (LAI-AMT group). A group of 20\u00a0remitted schizophrenic subjects with oral AMT and matching main sociodemographic, clinical and treatment variables made up the control group (oral-AMT group). All participants were assessed in terms of objective (PANSS, YMRS, MADRS) and subjective (SWN-K, DAI-10, SF-36) treatment outcomes at baseline (T0) and after 6\u00a0months (T1).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800068619_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Between T0 and T1, general psychopathology of the PANSS, DAI-10, and all but one of the SWN-K dimensions (except for social integration), showed significantly higher percentages of improvement in the LAI-AMT group compared to the oral-AMT group. A generalized expansion of health-related quality of life, with better functioning in almost all areas of daily living, was reported by the LAI-AMT group after the 6-month period. In contrast, the oral-AMT group reported a significant worsening of health-related quality of life in the areas of emotional role and social functioning in the same period.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800068619_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Our study indicates possible advantages of LAI over oral antipsychotic formulation in terms of subjective experience of maintenance treatment in remitted schizophrenic patients. Size and duration of this study need to be expanded in order to produce more solid and generalizable results.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T16:09:09Z","timestamp":1468944549000},"page":"35-42","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment"],"prefix":"10.1017","volume":"37","author":[{"given":"F.","family":"Pietrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.A.","family":"Talamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Andrisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Boncompagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ballerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"S0924933800068619_bib0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.04.008"},{"key":"S0924933800068619_bib0029","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-005-0838-9"},{"key":"S0924933800068619_bib0009","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00154-1"},{"key":"S0924933800068619_bib0012","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1007"},{"key":"S0924933800068619_bib0011","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2010.545984"},{"key":"S0924933800068619_bib0031","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000160"},{"key":"S0924933800068619_bib0013","doi-asserted-by":"publisher","DOI":"10.3109\/15622971003690289"},{"key":"S0924933800068619_bib0028","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315596897"},{"key":"S0924933800068619_bib0038","unstructured":"[38] Eli Lilly and Company. ZypAdhera. Summary of product characteristics, EU. 2012."},{"key":"S0924933800068619_bib0022","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182a6a142"},{"key":"S0924933800068619_bib0024","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1108"},{"key":"S0924933800068619_bib0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2009.05.004"},{"key":"S0924933800068619_bib0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60239-6"},{"key":"S0924933800068619_bib0023","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-992140"},{"key":"S0924933800068619_bib0039","unstructured":"[39] Janssen-Cilag. Xeplion. Summary of product characteristics, EU. 2012."},{"key":"S0924933800068619_bib0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(14)70001-X"},{"key":"S0924933800068619_bib0007","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00544.x"},{"key":"S0924933800068619_bib0015","doi-asserted-by":"publisher","DOI":"10.1159\/000232973"},{"key":"S0924933800068619_bib0040","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-340"},{"key":"S0924933800068619_bib0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.02.003"},{"key":"S0924933800068619_bib0051","first-page":"164","article-title":"Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study","volume":"28","author":"Barrio","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"S0924933800068619_bib0045","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6890.1437"},{"key":"S0924933800068619_bib0018","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2014.988268"},{"key":"S0924933800068619_bib0041","volume-title":"Structured clinical interview for DSM-IV-TR Axis\u00a0I disorders, research version, patient edition (SCID-I\/P)","author":"First","year":"2002"},{"key":"S0924933800068619_bib0021","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-221"},{"key":"S0924933800068619_bib0034","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S0924933800068619_bib0003","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"S0924933800068619_bib0004","first-page":"1138","article-title":"Continuous versus targeted medication in schizophrenic outpatients: outcome results","volume":"147","author":"Carpenter","year":"1990","journal-title":"Am J Psychiatry"},{"key":"S0924933800068619_bib0042","unstructured":"[42] American psychiatric association Diagnostic and statistical manual of mental disorder (DSM-IV) 4th ed. American psychiatric press Washington, DC [Text revision]"},{"key":"S0924933800068619_bib0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00059-1"},{"key":"S0924933800068619_bib0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"S0924933800068619_bib0010","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2007.58.9.1187"},{"key":"S0924933800068619_bib0014","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S53795"},{"key":"S0924933800068619_bib0016","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418130-00004"},{"key":"S0924933800068619_bib0017","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620040-00003"},{"key":"S0924933800068619_bib0019","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0083-9"},{"key":"S0924933800068619_bib0020","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"S0924933800068619_bib0025","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s03"},{"key":"S0924933800068619_bib0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2013.05.011"},{"key":"S0924933800068619_bib0026","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312464106"},{"key":"S0924933800068619_bib0027","doi-asserted-by":"publisher","DOI":"10.2165\/11599080-000000000-00000"},{"key":"S0924933800068619_bib0052","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12017"},{"key":"S0924933800068619_bib0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.012"},{"key":"S0924933800068619_bib0032","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"S0924933800068619_bib0033","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S0924933800068619_bib0035","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"S0924933800068619_bib0037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0447.2005.00659.x","article-title":"Standardized remission criteria in schizophrenia","volume":"113","author":"van Os","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"S0924933800068619_bib0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.02.008"},{"key":"S0924933800068619_bib0044","volume-title":"SF-36 health survey manual and interpretation guide","author":"Ware","year":"1997"},{"key":"S0924933800068619_bib0046","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835b091f"},{"key":"S0924933800068619_bib0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.12.020"},{"key":"S0924933800068619_bib0054","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913001016"},{"key":"S0924933800068619_bib0055","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S77778"},{"key":"S0924933800068619_bib0002","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312474019"},{"key":"S0924933800068619_bib0048","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314542098"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933816300232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933816300232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800068619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T08:28:13Z","timestamp":1584952093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800068619\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":55,"alternative-id":["S0924933800068619"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2016.05.008","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment","name":"articletitle","label":"Article Title"},{"value":"European Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eurpsy.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}